Aims 5
A set of 41 paediatric prescribing indicators describing potential harm for the hospital setting 23 have been identified by an expert panel. The indicators provide a standardised method of 24 evaluation of prescribing data on both paper and electronic systems. They can also be used 25 to assess implementation of clinical decision support systems or other quality improvement 26
initiatives. 27
What is already known about this subject 28  Prescribing errors are common in the paediatric setting 29  Prescribing indicators can be used to measure or monitor the accuracy of prescribing 30  There are no validated paediatric prescribing indicators for the hospital setting 31
What this study adds 32
Introduction 37
The use of medication to treat disease, alleviate symptoms and prevent illness is the most 38 common intervention used in healthcare. The vast majority of medication does not cause 39
harm. However, all medicines carry some level of risk. Medication errors are common in 40 hospital practice 1 and evidence suggests possibly more common in children. 2 Determining 41 the harm caused by these errors is vital to be able to understand how interventions might be 42 targeted to reduce the risk of harm. Methods for determining harm vary considerably. Some 43 studies use a severity scale for determining harm, scored by the researcher or by obtaining 44 consensus between a number of healthcare professionals.
3, 4

45
The same methodologies for identifying prescribing errors and harm in adult patients have 46 been used in the paediatric setting. Prescription review often by hospital pharmacists yields 47 large numbers of potential prescribing errors often with low or no harm. 4, 5 This make is 48 difficult to determine the impact of any change or improvement. 49
Trigger tools look for indicators of harm rather than specific errors, for example a high 50
International Normalised Ratio (INR) indicates that a potential error with warfarin may have 51 occurred and requires checking to confirm this. Triggers for the paediatric setting have been 52 described in the literature. Stockwell et al recently published a paediatric harm 53 measurement tool contained 51 triggers, including 21 medication related triggers. 6 Trigger 54 tools such as this provide a standard method of identifying errors but they require extensive 55 retrospective case note review in order to identify firstly the trigger and then any subsequent 56 medication related harm. 57
Prescribing indicators are a valid standardised way of measuring or monitoring an area of 58 prescribing where changes in prescribing or putative improvement require evaluation either 59 prospectively or retrospectively. Adult prescribing indicators have been developed in several 60 settings in the UK.
7-10 Thomas et al 11 published a set of adult prescribing indicators for the 61 hospital setting. Using an eDelphi methodology, consensus on a set of 81 indicators was 62 achieved. They describe prescribing errors which have the risk of causing significant harm. 63
The aim of this research was to create a set of paediatric prescribing indicators for the 64 hospital setting that can be used to assess the impact of electronic prescribing.
Method 66
While evidence-based medicine is the gold standard approach to care, there, remain vast 67 swathes of medicine where evidence is lacking or incomplete. This is often due to the rare 68 nature of a condition and the subsequent difficulty in running a randomised controlled trial. The eDelphi Process 110
Exploratory Round 111
The 24 panellists were sent the initial list of indicators for the exploratory round. They were 112 instructed to review each indicator for relevance and possible modification to ensure clarity. 113
They also had the opportunity at this stage to suggest additional indicators that had not been 114 identified by the research team. The additional indicators were collated and reviewed and, if 115 appropriate, included in the final indicator list used for round one of the eDelphi process. 116
Panellists were also made aware of the reasons for exclusion of any suggested indicators. 117
Round One 118
In round one panellists were asked to rate each indicator for its likelihood of occurrence and 119 severity of harm should it occur. The scoring system used was based on the National 120 Patient Safety Agency scale in common use in UK hospitals REF (Table 1) and allowed 121 identification of indicators with the greatest clinical risk. The panellist scores were converted 122 into a risk score using the matrix. The median risk scores for each indicator were then 123 calculated, allowing the indicators to be divided into groups based on their risk scores. 124
Round Two 125
In round two, each panellist was sent the indicators, the median likelihood and severity 126 scores from the panel and the individual panellist's original scores from round 1. Panellists 127
were then asked to review their scores in light of the median scores and were given the 128 opportunity to either maintain their original judgement or modify their scores in line with the 129 majority of the group. The median scores were then re-calculated for each indicator and thelevel of consensus determined. Indicators with a median risk score greater than 8 (high or 131 extreme) and at least 80% consensus were then considered to have achieved an adequate 132 level of consensus and therefore inclusion into the final list. 133
Results
134
Prior to the exploratory round, a total of 179 potential indicators were identified from the 135 resources listed above (Table 1 ). The research team reviewed each indicator against the 136 inclusion and exclusion criteria resulting in a final list of 100 indicators; 77 indicators were 137 identified from a single source, 23 from two or more sources. 138
The exploratory stage and rounds one and two were completed by 21 of the 24 panellists 139 who had originally agreed to take part. Table 3 The most frequent error type identified as high risk was dosing (n= 19) with drug-drug 158 interactions (n=7) and clinical contraindications (n=6) the next two most frequent error types. 159
Discussion 160
The eDelphi process has identified 41 high risk prescribing indicators for the paediatric 161 hospital setting. They can potentially be used to monitor the impact of electronic prescribingor clinical decision support tools. To the authors' knowledge, this is the first set of 163 prescribing indicators for paediatric patients in the hospital setting. However, other work has 164 attempted to identify high risk medicines in this setting. 165
The consensus process used to derive the indicators involved a panel consisting of 21 166 paediatricians and paediatric pharmacists all of whom complete two rounds of scoring, 167 limiting any bias introduced by missing responses. 168
Nearly half (n = 19) of the final 41 indicators related to dosing errors. This is not surprising 169 since dose errors account for the majority of the indicators identified for rounds 1 and 2. 170 This is likely influenced by the fact that dosing errors are the most common error type 171 reported in paediatrics. [21] [22] [23] Drugs with known risks such as gentamicin, phenytoin and 172 methotrexate were included in the dosage indicators; however, "lower risk" drugs such as 173 meropenem, ceftriaxone and domperidone are also present. This may reflect, in the case of 174 the antimicrobials, the relatively serious clinical indications in which these drugs are used 175 and the need to prescribe the correct dose to avoid treatment failure as well as heightened 176 awareness as a result of antimicrobial stewardship. Or; in the case of domperidone the 177 relatively recent publicity relating to adverse reactions. The indicators can also be used to optimise the capability of electronic prescribing systems, 218 such as with the provision of complex clinical decision support to highlight and avert such 219 errors at the point of prescribing. This also has the potential to focus alerts on high risk 220 areas, with the advantage of reducing alert fatigue. Without this knowledge, it is difficult to target quality improvement projects, and also inform 240 under-and postgraduate education of paediatric prescribing. 241
They could also be used to refine alerting systems used in electronic prescribing to target 242 warnings and alleviate alert fatigue. 243
The use of these paediatric indicators in combination with previously described adult 244 indicators for the hospital setting provides a comprehensive tool that can be used to evaluate 245 
